Sunstone LSV Fund II portfolio company VAXIMM AG, a Swiss-German biotech company focused on developing oral T-cell immunotherapies, today announced the appointment of Dr. Jarl Ulf Jungnelius, MD, PhD to the newly created position of Chief Medical Officer.

Dr. Jungnelius is a seasoned healthcare professional, having spent over thirty years practicing medicine and leading key drug development projects for international pharmaceutical companies, with a strong focus on oncology.